Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic cell therapies: specialized cells made from established cell lines for potential transplantation into patients. Its pipeline includes programs for retinal disease and spinal cord injury, alongside earlier-stage hearing, corneal, and research initiatives. These therapies are investigational—not approved treatments—and company-reported clinical observations do not establish that a therapy works.
What does Lineage Cell Therapeutics do?
Lineage develops cell replacement and support therapies. Its intended approach is to produce human cells associated with particular developmental lineages and transplant them where disease, aging, or injury has left cells absent or dysfunctional. The company describes this approach and its AlloSCOPE platform on its company overview and platform page.
Lineage is a biotechnology developer, not a provider of an approved consumer cell-therapy treatment. Its program descriptions and reported observations should be understood as company-reported information about investigational development.
How does an off-the-shelf cell therapy work?
Lineage says it starts with established, self-renewing pluripotent cell lines, then uses directed differentiation protocols to produce specialized cell types. Pluripotent cells can develop into many cell types; directed differentiation is the process of guiding them toward a chosen type, such as retinal pigment epithelial cells or oligodendrocyte progenitor cells.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
- Allogeneic means the donor-derived cells are intended for recipients other than the original donor.
- Off-the-shelf describes a development model based on producing cells from established cell lines, rather than making a bespoke cell product from each intended recipient. It does not mean an approved treatment is currently available to buy.
- Transplantation is intended to replace or support cells affected by a disease or injury. The proposed role and potential benefit depend on the particular cell type and condition being studied.
This is the company’s platform rationale, not proof that transplanted cells restore function or provide a clinical benefit. Each program must be assessed by what its studies measure and what results have actually been reported.
What is Lineage Cell Therapeutics’ pipeline?
The pipeline is best understood by separating clinical-stage programs from preclinical work and research initiatives. The stages below reflect Lineage’s cited program descriptions and March 2026 filing; development details can change.
| Program | Target cells and intended use | Stage or study focus | Partner information |
|---|---|---|---|
| OpRegen / RG6501 | Retinal pigment epithelial (RPE) cells for geographic atrophy secondary to age-related macular degeneration | Phase 2a development; GAlette evaluates subretinal delivery, safety, and activity | Worldwide collaboration with Roche and Genentech |
| OPC1 | Oligodendrocyte progenitor cells for spinal cord injury | DOSED evaluates the safety and utility of a delivery device; earlier trials have long-term follow-up | Not stated on the cited program page |
| ReSonance (ANP1) | Auditory neuron progenitor cells for sensorineural hearing loss | Preclinical | Research collaboration with William Demant Invest |
| COR1 | Corneal endothelial cells; expected indications include Fuchs endothelial corneal dystrophy and bullous keratopathy | Stage not stated in the cited program materials | Not stated |
| PNC1, RND1, ILT1 | Research initiatives listed in Lineage’s March 2026 Form 8-K | Research initiatives; further stage and focus details are not established here | Not stated |
Sources: Lineage’s OpRegen, OPC1, and other programs pages, and its March 2026 Form 8-K.
What is OpRegen?
OpRegen, also identified as RG6501, is an allogeneic RPE cell replacement therapy being developed for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a form of dry AMD. Lineage describes the program as being in Phase 2a under a worldwide collaboration with Roche and Genentech.
Recommended Free Tools
Rank #3
What the GAlette study assesses
The GAlette study evaluates subretinal surgical delivery, safety, and activity. Its stated primary objectives include whether cells can be delivered to target retinal regions and assessment of procedure-related adverse events. Structural imaging is among the secondary assessments. These measures describe what the study evaluates; they should not be mistaken for evidence of confirmed efficacy.
How to interpret the reported visual-acuity observations
Lineage reported that Phase 1/2a Cohort 4 participants with less advanced GA had a mean best-corrected visual acuity change of +6.2 ETDRS letters among 10 treated eyes completing three-year follow-up. Within that report, five participants with extensive treatment coverage had a reported mean change of +9.0 letters. These are small-cohort, company-reported observations, not results that can be generalized to all patients or treated as proof of efficacy. Lineage also describes structural observations from retinal imaging. See the OpRegen program page for the company’s account.
What is OPC1?
OPC1 is an allogeneic oligodendrocyte progenitor cell therapy being developed for spinal cord injury. Lineage’s stated rationale is to replace or support cells in the injured spinal cord.
What the DOSED study measures
Lineage describes DOSED as evaluating the safety and utility of a novel device for delivering OPC1 to the injury area in people with subacute and chronic spinal cord injury. A study focused on a delivery device is not, by itself, evidence that the cell therapy restores function.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsEarlier clinical trial history
Lineage reports a five-person Phase 1 safety trial in acute thoracic injury and a 25-person Phase 1/2a trial in subacute cervical injury, with long-term follow-up. Those trial histories are company-reported; the cited program description does not establish that OPC1 is an approved treatment or demonstrate restored function. Further program details are on the OPC1 page.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Which programs are earlier-stage?
ReSonance (ANP1)
ReSonance is an auditory neuron progenitor cell transplant program for sensorineural hearing loss. Lineage describes it as preclinical and reports a research collaboration with William Demant Invest.
COR1 and other research initiatives
COR1 is a corneal endothelial cell program. Lineage lists Fuchs endothelial corneal dystrophy and bullous keratopathy among its expected indications, but the cited materials do not establish a development stage here. The company’s March 2026 Form 8-K also lists PNC1, RND1, and ILT1 as research initiatives. The company’s other programs page and March 2026 filing provide the cited descriptions.
How should readers compare the programs?
Do not rank the programs by implied likelihood of success. Compare what each aims to do, how far its development has progressed, and what its studies actually assess.
- Target and intended role: OpRegen targets RPE cells in GA secondary to AMD; OPC1 targets oligodendrocyte progenitor cells in spinal cord injury; ReSonance targets auditory neuron progenitor cells in hearing loss.
- Development stage: OpRegen is described as Phase 2a, OPC1 has a device-focused study and follow-up from earlier trials, and ReSonance is preclinical. COR1 and the listed research initiatives should not be assigned a stage beyond what the cited materials state.
- What is measured: GAlette includes delivery to target retinal regions, procedure-related adverse events, and secondary structural imaging. DOSED focuses on the safety and utility of a delivery device. Study measures and company observations are not interchangeable with confirmed clinical benefit.
- Collaboration: Lineage identifies Roche and Genentech with OpRegen and William Demant Invest with ReSonance. The cited program descriptions do not state a partner for OPC1 or COR1.
What the pipeline does—and does not—tell you
A pipeline is a snapshot of development programs, not a list of available treatments or a forecast of which candidates will succeed. Lineage’s descriptions explain the cell types it is developing, the conditions it hopes to address, and selected study activities. The cited evidence does not establish regulatory approval or prove that the therapies deliver clinical benefit. For current enrollment, protocol status, and stage, consult the latest company filings and trial records, because those details can change.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
